Irish medical technology firm Medtronic has received approval from the US Food and Drug Administration (FDA) for its VenaSeal closure system.
The company has developed a minimally invasive procedure to close lower superficial extremities such as the great saphenous vein in patients with symptomatic venous reflux.
Medtronic aortic and peripheral vascular business endoVenous franchise general manager and vice-president Sandra Lesenfants said: "The FDA approval of the VenaSeal system strengthens our endoVenous portfolio, providing physicians and their patients with a non-tumescent treatment option.
"The VenaSeal System, together with our Venefit procedure, provides physicians and patients with leading treatment options."
According to Medtronic, the VenaSeal procedure is the only non-tumescent, non-thermal and non-sclerosant procedure approved in the US, which uses a specially formulated medical adhesive that closes the vein.
The VenaSeal system also received approval in the Australia, Canada, Europe and Hong Kong and around 2,000 patients were treated with the system.
The company is planning the US launch of the system in this spring.
Also called as chronic venous insufficiency, Venous reflux disease occurs when valves in the veins of the lower leg does not function properly.